Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap 2-dong, Songpa-gu, Seoul, 138-736, Korea.
J Cancer Res Clin Oncol. 2012 Sep;138(9):1561-7. doi: 10.1007/s00432-012-1230-2. Epub 2012 May 1.
To evaluate the impact of surgical waiting time (SWT) on outcomes of patients who underwent radical nephrectomy for stage II or higher renal cell carcinoma (RCC).
Of the 1,732 patients who underwent surgery for RCC between 1989 and 2007, medical records of 319 with clinical stage II or higher RCC without distant metastases were retrospectively reviewed. Ten patients with SWT greater than 3 months were excluded from analysis, and we compared pathological upstaging and survival rates between patients with SWT <1 month (234/319, 73.3 %) and 1-3 months (75/319, 23.5 %).
Clinicopathological characteristics between two groups were not different except the presence of symptom. The pathological upstaging was higher in patients with SWT of 1-3 months but statistically not significant. SWT of 1-3 months was not an independent predictor of pathological upstaging, recurrence-free survival (RFS; p = 0.896), or cancer-specific survival (CSS; p = 0.737). On subgroup analysis by TNM stage (cT2NxcM0 and cT3-4NxcM0), SWT of 1-3 months was not an independent predictor of pathological upstaging and was not associated with RFS or CSS. SWT, treated as a continuous variable, was also not an independent predictor of outcome in any subgroup. Similar results were found in symptomatic patients.
The outcomes of patients with prolonged SWT did not differ from those of most patients who underwent nephrectomy within 1 month. In patients with stage II or higher RCC who underwent nephrectomy within 3 months after diagnosis, prolonged SWT was not an independent predictor of pathological upstaging, RFS, or CSS.
评估手术等待时间(SWT)对接受根治性肾切除术治疗 II 期或更高分期肾细胞癌(RCC)患者结局的影响。
在 1989 年至 2007 年间接受 RCC 手术的 1732 名患者中,回顾性分析了 319 名临床分期 II 期或更高分期且无远处转移的 RCC 患者的病历。排除 SWT 大于 3 个月的 10 名患者,比较 SWT<1 个月(234/319,73.3%)和 1-3 个月(75/319,23.5%)的患者的病理升级和生存率。
两组的临床病理特征除症状外无差异。SWT 为 1-3 个月的患者病理升级率较高,但无统计学意义。SWT 为 1-3 个月不是病理升级的独立预测因素,与无复发生存率(RFS;p=0.896)或癌症特异性生存率(CSS;p=0.737)无关。按 TNM 分期(cT2NxcM0 和 cT3-4NxcM0)进行亚组分析,SWT 为 1-3 个月不是病理升级的独立预测因素,也与 RFS 或 CSS 无关。SWT 作为连续变量也不能预测任何亚组的结局。在有症状的患者中也得到了类似的结果。
SWT 延长的患者结局与大多数在 1 个月内接受肾切除术的患者无差异。在诊断后 3 个月内接受肾切除术的 II 期或更高分期 RCC 患者中,SWT 延长不是病理升级、RFS 或 CSS 的独立预测因素。